Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Kontrol Technologies Corp N.KNR

Alternate Symbol(s):  KNRLF

Kontrol Technologies Corp. is a provider of energy management, continuous air quality and emission solutions to commercial and industrial consumers. It delivers building intelligence through the Internet of things (IoT), software and cloud technology as well as project integration. Its smart technology is deployed to customers through a cloud-based interface accessible on desktops and mobile... see more

NEO:KNR - Post Discussion

Kontrol Technologies Corp > Air Monitor Can Detect COVID-19 Variants in Five Minutes
View:
Post by okgonow on Oct 24, 2023 2:52pm

Air Monitor Can Detect COVID-19 Variants in Five Minutes

Bah Bye BIO CLOUD

https://www.techbriefs.com/component/content/article/tb/pub/briefs/bio-medical/49230


The monitor uses a biosensor made with nanobodies that is integrated into an air sampler that operates based on the wet cyclone technology.

Now that the emergency phase of the COVID-19 pandemic has ended, scientists are looking at ways to surveil indoor environments in real time for viruses. By combining recent advances in aerosol sampling technology and an ultrasensitive biosensing technique, researchers at Washington University in St. Louis have created a real-time monitor that can detect any of the SARS-CoV-2 virus variants in a room in about five minutes.

Results of their work on the monitor, which they say is the most sensitive detector available, were published in Nature Communications.

“There is nothing at the moment that tells us how safe a room is,” said Neurology Professor John Cirrito. “If you are in a room with 100 people, you don’t want to find out five days later whether you could be sick or not. The idea with this device is that you can know essentially in real time, or every five minutes, if there is a live virus.”

Cirrito and Carla Yuede, an Associate Professor of Psychiatry, had previously developed a micro-immunoelectrode (MIE) biosensor that detects amyloid beta as a biomarker for Alzheimer’s disease and wondered if it could be converted into a detector for SARS-CoV-2. They reached out to Rajan Chakrabarty, the Harold D. Jolley Career Development Associate Professor of Energy, Environmental, and Chemical Engineering in McKelvey Engineering, who assembled a team that included Joseph Puthussery, a postdoctoral research associate in Chakrabarty’s lab who had expertise in building real-time instruments to measure the toxicity of air.

To convert the biosensor from detecting amyloid beta to coronavirus, the researchers exchanged the antibody that recognizes amyloid beta for a nanobody from llamas that recognizes the spike protein from the SARS-CoV-2 virus. David Brody, MD, PhD, and an author on the paper, developed the nanobody in his lab at the National Institutes of Health (NIH). The nanobody is small, easy to reproduce and modify and inexpensive to make, the researchers said.

“The nanobody-based electrochemical approach is faster at detecting the virus because it doesn’t need a reagent or a lot of processing steps,” Yuede said. “SARS-CoV-2 binds to the nanobodies on the surface, and we can induce oxidation of tyrosines on the surface of the virus using a technique called square wave voltammetry to get a measurement of the amount of virus in the sample.”

Chakrabarty and Puthussery integrated the biosensor into an air sampler that operates based on the wet cyclone technology.

“The challenge with airborne aerosol detectors is that the level of virus in the indoor air is so diluted that it even pushes toward the limit of detection of polymerase chain reaction (PCR) and is like finding a needle in a haystack,” Chakrabarty said. “The high virus recovery by the wet cyclone can be attributed to its extremely high flow rate, which allows it to sample a larger volume of air over a five-minute sample collection compared with commercially available samplers.”

The team’s monitor has a flow rate of about 1,000 liters per minute, making it one of the highest flow-rate devices available. It is also compact at about 1 foot wide and 10 inches tall and lights up when a virus is detected.

The team tested the monitor in the apartments of two COVID-positive patients. The real-time PCR results of air samples from the bedrooms were compared with air samples collected from a virus-free control room. The devices detected RNA of the virus in the air samples from the bedrooms but did not detect any in the control air samples.

In laboratory experiments that aerosolized SARS-CoV-2 into a room-sized chamber, the wet cyclone and biosensor were able to detect varying levels of airborne virus concentrations after only a few minutes of sampling.

“We are starting with SARS-CoV-2, but there are plans to also measure influenza, RSV, rhinovirus, and other top pathogens that routinely infect people,” Cirrito said. “In a hospital setting, the monitor could be used to measure for staph or strep, which cause all kinds of complications for patients. This could really have a major impact on people’s health.”

The team is working to commercialize the air quality monitor.

Comment by Mostlyserious on Oct 27, 2023 5:58pm
Interesting.  They say there is nothing on the market that tells how the room is.  Like BioClous never existed.  And they comment that the PCR technology applied to air flow is like looking for a needle in the haystack. While clearly there is no mention of BioCloud here, my sense is that Health Canada could not find that needle in the haystack with BioCloud and the technology is ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities